[go: up one dir, main page]

RU2001132335A - METHOD FOR ESTIMATING THE RISK OF A PEPTIC ULCER, INCLUDING THE STAGES OF QUANTITATIVE DETERMINATION OF THE CONCENTRATION OF PEPPSINOGEN I (PGI) AND GASTRIN-17 IN THE SERUM SAMPLE - Google Patents

METHOD FOR ESTIMATING THE RISK OF A PEPTIC ULCER, INCLUDING THE STAGES OF QUANTITATIVE DETERMINATION OF THE CONCENTRATION OF PEPPSINOGEN I (PGI) AND GASTRIN-17 IN THE SERUM SAMPLE

Info

Publication number
RU2001132335A
RU2001132335A RU2001132335/14A RU2001132335A RU2001132335A RU 2001132335 A RU2001132335 A RU 2001132335A RU 2001132335/14 A RU2001132335/14 A RU 2001132335/14A RU 2001132335 A RU2001132335 A RU 2001132335A RU 2001132335 A RU2001132335 A RU 2001132335A
Authority
RU
Russia
Prior art keywords
gastrin
concentration
pepsinogen
risk
serum
Prior art date
Application number
RU2001132335/14A
Other languages
Russian (ru)
Other versions
RU2225615C2 (en
Inventor
Пентти Сиппонен
Матти Хяркенен
Осмо Суованиеми
Эрик ФОРСБЛОМ
Original Assignee
Биохит Ойй
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI990992A external-priority patent/FI118653B/en
Application filed by Биохит Ойй filed Critical Биохит Ойй
Publication of RU2001132335A publication Critical patent/RU2001132335A/en
Application granted granted Critical
Publication of RU2225615C2 publication Critical patent/RU2225615C2/en

Links

Claims (9)

1. Способ оценки наличия риска пептической язвы у индивидуума, причем способ включает в себя этапы количественного определения концентрации пепсиногена I и гастрина-17 в образце сыворотки указанного индивидуума, выбора специфической для способа эталонной величины и величины отсечки для соответствующих анализируемых веществ, сравнения определяемых таким образом концентраций пепсиногена I и гастрина-17 со специфической для способа эталонной величиной и величиной отсечки, в результате которого сывороточная концентрация пепсиногена I и гастрина-17 выше верхнего предела соответствующей эталонной величины или сывороточная концентрация пепсиногена I выше верхнего предела ее эталонной величины в комбинации с концентрацией гастрина-17 в пределах эталонного диапазона или ниже ее величины отсечки, указывает на возросший риск пептической язвы у указанного индивидуума.1. A method for assessing the risk of peptic ulcer in an individual, the method comprising the steps of quantifying the concentration of pepsinogen I and gastrin-17 in a serum sample of the indicated individual, selecting a method-specific reference value and cut-off value for the corresponding analytes, comparing so determined concentrations of pepsinogen I and gastrin-17 with a method-specific reference value and cut-off value, as a result of which the serum concentration of pepsinogen I and ha trine-17 above the upper limit of respective reference value, or a serum pepsinogen I concentration above the upper limit of its reference value in combination with a gastrin-17 concentration within the reference range or below its cut-off value, indicates an increased risk of peptic ulcer in said individual. 2. Способ по п.1, при котором в образце сыворотки проводится также определение антитела к Helicobacter pylori.2. The method according to claim 1, in which the determination of antibodies to Helicobacter pylori is also carried out in a serum sample. 3. Способ по п.1, при котором концентрацию гастрина-17 в сыворотке также измеряют с использованием теста белковой стимуляции путем измерения указанной концентрации в ситуации до и после поглощения богатого белком стандартного блюда, причем отсутствие реакции указывает на риск развития язвы желудка.3. The method according to claim 1, in which the concentration of gastrin-17 in serum is also measured using the protein stimulation test by measuring the specified concentration in the situation before and after absorption of a protein-rich standard dish, and the absence of a reaction indicates a risk of gastric ulcer. 4. Способ по пп.1, 2 или 3, при котором пепсиноген I и гастрин-17 определяется иммунологически с использованием пластиковой, стеклянной или целлюлозной подложки.4. The method according to claims 1, 2 or 3, wherein pepsinogen I and gastrin-17 are determined immunologically using a plastic, glass or cellulose substrate. 5. Способ по п.4, при котором подложка представляет собой микропланшет.5. The method according to claim 4, wherein the substrate is a microplate. 6. Способ по любому из пп.1-5, при котором способ выявления, основанный на измерении оптического поглощения, флуоресценции или люминесценции, используется для определения пепсиногена I и гастрина-17.6. The method according to any one of claims 1 to 5, wherein the detection method, based on the measurement of optical absorption, fluorescence or luminescence, is used to determine pepsinogen I and gastrin-17. 7. Способ по любому из пп.4-6, при котором для определения концентрации пепсиногена I используется поликлональное или моноклональное антитело против пепсиногена I.7. The method according to any one of claims 4 to 6, wherein a polyclonal or monoclonal anti-pepsinogen I antibody is used to determine the concentration of pepsinogen I. 8. Способ по любому из пп.4-7, при котором для определения концентрации гастрина-17 используется поликлональное или моноклональное антитело против гастрина-17.8. The method according to any one of claims 4 to 7, wherein a polyclonal or monoclonal anti-gastrin-17 antibody is used to determine the concentration of gastrin-17. 9. Способ по любому из предшествующих пунктов, при котором способы определения пепсиногена I, гастрина-17 и Helicobacter pylori комбинируются в набор-способ, в котором определения осуществляются одновременно на микропланшете с использованием поликлональных или моноклональных антител, а также способов выявления, основанных на поглощении, флуоресценции или люминесценции.9. The method according to any one of the preceding paragraphs, wherein the methods for determining pepsinogen I, gastrin-17 and Helicobacter pylori are combined into a kit-method, in which the determination is carried out simultaneously on a microplate using polyclonal or monoclonal antibodies, as well as detection methods based on absorption fluorescence or luminescence.
RU2001132335/15A 1999-04-30 2000-04-28 Method for differentiation between the risk in developing gastric ulcer and duodenal ulcer RU2225615C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI990992A FI118653B (en) 1999-04-30 1999-04-30 Procedure for determining the risk of peptic ulcer
FI990992 1999-04-30

Publications (2)

Publication Number Publication Date
RU2001132335A true RU2001132335A (en) 2003-08-27
RU2225615C2 RU2225615C2 (en) 2004-03-10

Family

ID=8554567

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001132335/15A RU2225615C2 (en) 1999-04-30 2000-04-28 Method for differentiation between the risk in developing gastric ulcer and duodenal ulcer

Country Status (13)

Country Link
US (1) US6872543B1 (en)
EP (1) EP1173770B1 (en)
JP (1) JP4598959B2 (en)
CN (1) CN100573152C (en)
AT (1) ATE300053T1 (en)
AU (1) AU4299800A (en)
DE (1) DE60021369T2 (en)
DK (1) DK1173770T3 (en)
ES (1) ES2241597T3 (en)
FI (1) FI118653B (en)
PT (1) PT1173770E (en)
RU (1) RU2225615C2 (en)
WO (1) WO2000067035A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20010019A7 (en) 2001-01-05 2002-07-06 Biohit Oyj Method for diagnosing atrophic gastritis
AU2002252456A1 (en) * 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
EP1416964A4 (en) * 2001-07-09 2005-10-12 Aphton Corp Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
SE0200974D0 (en) * 2002-03-27 2002-03-27 Phagen Ab Screening method for gastritis
FI119571B (en) * 2002-09-06 2008-12-31 Biohit Oyj Procedure for detecting a risk of esophagitis or Barrett's esophagus in an individual
EP1608984A2 (en) * 2003-03-28 2005-12-28 Aphton Corporation Gastrin hormone immunoassays
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
FI119572B (en) * 2004-03-05 2008-12-31 Biohit Oyj Method for predicting the condition of the gastric mucosa
US8158128B2 (en) 2004-09-22 2012-04-17 Cancer Advances, Inc. Monoclonal antibodies to progastrin
US8272265B2 (en) * 2005-07-12 2012-09-25 Technion Research And Development Foundation Ltd. System and method for active detection of asymmetry in rotating structures
EP2203745A4 (en) * 2007-10-26 2010-12-08 Biohit Oyj Methods and products for diagnosing autoimmune diseases and gastric cancer linked with atrophic gastritis
RU2465597C1 (en) * 2011-04-08 2012-10-27 Сергей Михайлович Котелевец Method for determining probability of developing stomach cancer
RU2582565C1 (en) * 2015-03-06 2016-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации /ГБОУ ВПО ОрГМУ Минздрава России/ Method for differential diagnosis of gastric and duodenal ulcers
CN104820096B (en) * 2015-04-30 2017-04-19 必欧瀚生物技术（合肥）有限公司 Combined standard quantity for determining quantity of marker used in early gastric cancer risk detection and application thereof in early gastric cancer screening
CN107271669A (en) * 2016-09-23 2017-10-20 清华大学深圳研究生院 Propepsin, helicobacter pylori antibody and G17 detection method and its kit
CN107328938A (en) * 2016-09-23 2017-11-07 清华大学深圳研究生院 Propepsin and helicobacter pylori antibody detection method and its kit
JP6885581B2 (en) * 2017-02-06 2021-06-16 学校法人東京歯科大学 How to estimate the cutoff value in gastrin measurement
CA3066756A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
RU2677228C1 (en) * 2017-12-08 2019-01-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" Method of immunodiagnosis of gastroduodenal zone diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07304800A (en) * 1994-05-06 1995-11-21 Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk Monoclonal antibody against human pepsinogen
FI97304C (en) * 1994-11-16 1996-11-25 Locus Genex Oy Procedure for screening cancer risk
JP2949474B2 (en) * 1995-08-28 1999-09-13 隆久 古田 Method for determining eradication of Helicobacter pylori based on the rate of change of pepsinogen I/II ratio
JPH10148636A (en) * 1996-11-15 1998-06-02 Takahisa Furuta Method for judging elimination of germ of helicobacter pylori based on change rate of pepsinogen i/ii ratio

Similar Documents

Publication Publication Date Title
RU2001132335A (en) METHOD FOR ESTIMATING THE RISK OF A PEPTIC ULCER, INCLUDING THE STAGES OF QUANTITATIVE DETERMINATION OF THE CONCENTRATION OF PEPPSINOGEN I (PGI) AND GASTRIN-17 IN THE SERUM SAMPLE
CN106872420B (en) Kit and method for time-resolved fluorescence quantitative detection of microalbuminuria
CN111795956A (en) A method for judging the hook effect of homogeneous time-resolved fluorescence immunoassay
CN204165984U (en) Cardiac muscle troponin I immunochromatographiassay assay quantitative detection test paper
JP6810055B2 (en) How to reuse test probes and reagents in immunoassay
CN109459574A (en) For detecting the immuno-chromatographic test paper strip of saccharification hemoglobin content and comprising its immunoassay detection device
CN109061183A (en) A kind of time-resolved fluoroimmunoassay chromatography kit of five in one
JP2018522214A5 (en)
CN105988008A (en) Measurement device, kit and measurement method
JP4068148B2 (en) Assay method
CN109781972A (en) A kind of immunoquantitative detection method and application
DE69828646D1 (en) IMMUNOASSAY PROCEDURE AND TEST KIT
CA2366651A1 (en) A method for detecting megsin protein and use thereof
JP7483168B2 (en) Ferritin measurement reagent
CN209400549U (en) For detecting the immuno-chromatographic test paper strip of saccharification hemoglobin content and comprising its immunoassay detection device
DE3584114D1 (en) COMPOSITIONS FOR IMMUNO-ENZYMATIC TESTING OF PROSTAGLANDINS.
CN110988356A (en) C-reactive protein fast quantitative immunochromatographic test paper and preparation method thereof
CN116735511A (en) Method for fitting standard curve of enzymatic reaction analysis enzyme concentration
CA2097952A1 (en) Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence
JP2004012434A (en) Method for measuring pepsinogen and measuring kit
CN204287198U (en) Omnidistance C reactive protein immunochromatographiassay assay quantitative detection test paper
KR100491320B1 (en) Rapid measurement of fumonisin b1 oil using surface plasmon resonance
CN204514932U (en) Myoglobins immunochromatographiassay assay quantitative detection test paper
JP2595267B2 (en) Methods for measuring substances using photometric evaluation
CN115824980B (en) A microring resonator for detecting IgG protein in urine and its preparation method and application